• TPCA-1 and the NF-κB–Apaf1 Axis

  2026-08-16

  TPCA-1 offers a selective way to interrogate IKK-2-driven inflammation and its potential connection to the NF-κB/Apaf1/caspase-9/autophagy axis identified in septic acute kidney injury. This thought-leadership analysis translates evidence from rheumatoid arthritis models into a disciplined framework for testing tubular inflammation, apoptosis, and autophagy without overstating preclinical findings.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-15

  The reference study identifies hepatic soluble epoxide hydrolase as an upstream regulator of osteoclast differentiation through circulating 14,15-EET, 14,15-DHET, inflammatory cytokines, and the Nrf2–ARE pathway. Its combination of patient samples, ovariectomy-induced osteoporosis, liver-specific intervention, and cell-based experiments provides a mechanistic framework for studying the liver–bone axis and evaluating sEH inhibition in bone-loss research.

• MHY1485: mTOR Activator for Autophagy Assays

  2026-08-14

  MHY1485 provides a practical way to activate mTOR signaling while testing autophagy suppression, cell growth, and survival phenotypes. This workflow-focused guide connects pathway readouts with the LMP2A–mTORC1–GCNT3 findings reported in nasopharyngeal carcinoma and highlights controls that prevent misinterpreting LC3II accumulation.

• AS1842856 Foxo1 Inhibitor: Practical Workflow

  2026-08-14

  Use AS1842856 to isolate Foxo1 activity from upstream PI3K-Akt and epigenetic signals in metabolic, autophagy, and stem-cell assays. This workflow combines concentration planning, pathway-level controls, quantitative readouts, and troubleshooting for more interpretable inhibition-of-glucose-production studies.

• RapaLink-1 in Reliable mTOR Assays

  2026-08-13

  This scenario-based guide explains how RapaLink-1 (SKU A8764) can improve experimental planning for glioma growth inhibition, G0/G1 cell-cycle arrest, and mTOR pathway studies. It covers mechanism, concentration selection, solvent handling, data interpretation, and practical vendor-selection criteria.

• SM-164: Rethinking IAP Control of Tumor Cell Death

  2026-08-13

  SM-164 is a bivalent Smac mimetic that converts IAP antagonism into a testable sequence of cIAP degradation, TNFα-dependent apoptosis, caspase activation, and tumor-cell elimination. This thought-leadership analysis connects its established preclinical profile with more rigorous translational assay design and the emerging concept that regulated cell death can be triggered by protein loss independently of transcriptional shutdown.

• MLN4924 HCl salt: Assay Logic for RIPK3

  2026-08-12

  MLN4924 HCl salt provides a pharmacological route to test how NAE-dependent neddylation influences RIPK3 stability, necroptosis, and inflammation. This article translates viral degradation findings into a causal assay framework while defining controls, handling parameters, and interpretation limits.

• Hepatic sEH–Nrf2 Signaling in Osteoporosis

  2026-08-12

  Liu et al. identify a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2 activity, and promotes osteoclastogenesis in osteoporosis models. By combining patient samples, ovariectomy-induced osteoporosis mice, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, the study connects fatty acid epoxide signaling with redox imbalance and bone loss.

• Pazopanib: ATRX-Aware Assay Design in Glioma

  2026-08-11

  Pazopanib (GW-786034) offers a powerful framework for studying receptor tyrosine kinase signaling, angiogenesis inhibition, and ATRX-dependent drug sensitivity. This guide translates published glioma findings into practical, genotype-aware assay strategies for cancer research.

• Flavopiridol (L868275): CDK Inhibition Guide

  2026-08-11

  Flavopiridol, also known as L868275, is a pan-cyclin-dependent kinase inhibitor used as a cell cycle arrest agent in cancer research. Its product data support CDK1, CDK2, CDK4, CDK6, and CDK7 inhibition, while intestinal stem-cell evidence defines a separate tunicamycin-induced endoplasmic reticulum stress model.

• Candida auris Antifungal Pipeline: Systematic Review

  2026-08-10

  This systematic review maps the emerging antifungal pipeline for multidrug-resistant Candida auris, combining susceptibility data with evidence from neutropenic animal models. Its main contribution is a clinically relevant comparison of new agents, formulations, and mechanisms while highlighting the limits of current evidence and the need for therapies active against resistant isolates.

• Humanized Mice Clarify HD56 Prodrug Metabolism

  2026-08-09

  A 2025 Drug Metabolism and Disposition study shows that humanized-liver mice can resolve species differences in the conversion of the ester prodrug HD56 to HD561. By combining transporter, enzyme, microsomal, plasma, and pharmacokinetic experiments, the authors established a strong in vivo–in vitro correlation that supports more human-relevant preclinical assessment of carboxylesterase prodrugs.

• QPRT, MLCK, and Breast Cancer Invasion

  2026-08-08

  The reference study identifies quinolinate phosphoribosyltransferase (QPRT) as a metabolic enzyme associated with invasive breast cancer and links its activity to purinergic, Rho–ROCK–PLC, and myosin light chain kinase signaling. Genetic and pharmacological experiments indicate that QPRT promotes migration and invasion through increased myosin light chain phosphorylation, providing a mechanistic framework for studying metabolic control of tumor-cell motility.

• GM 6001 (Galardin) for ECM Research

  2026-08-07

  GM 6001, also called Galardin, gives researchers a practical way to suppress MMP-driven matrix degradation while separating extracellular remodeling from cell-intrinsic signaling and survival effects. Its broad activity supports meniscal healing research, EGFR transactivation inhibition, migration assays, and carefully controlled cancer studies.

• ATRX Loss Sensitizes High-Grade Glioma to Selective PDGFR In

  2026-08-07

  The reference study demonstrates that ATRX-deficient high-grade glioma cells are uniquely vulnerable to receptor tyrosine kinase and PDGFR inhibitors, highlighting a genotype-specific therapeutic opportunity. These findings suggest that stratifying glioma patients by ATRX mutation status could optimize the efficacy of targeted RTK inhibition strategies.

636 records 1/43 page Next 12345 下5页 Last page